JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operation and Financial Condition
On November2, 2017, Juniper Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results for the three-month period ended September30, 2017, entitled “Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results” (the “Press Release”). A copy of the Press Release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.
The information contained in this Item 2.02 of the Current Report on Form 8-K and Exhibit 99.1, shall not be deemed filed for the purposes of Section18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section18. Furthermore, such information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such filings.
Item 2.02. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. |
Description |
| 99.1 | Press Release dated November2, 2017, entitled “Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results”, furnished herewith. |
EXHIBIT INDEX
JUNIPER PHARMACEUTICALS INC ExhibitEX-99.1 2 d271657dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results CRINONE® Revenues Increased 19% and Juniper Pharma Services Revenues Increased 38% Year-over-Year Implemented Strategic Reprioritization BOSTON,…To view the full exhibit click here
About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)
Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women’s health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women’s health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.